Investigational Drugs Reduce Risk of Death from Ebola Virus Disease - National Institutes of Health
News Release Wednesday, November 27, 2019 Study Leaders Publish Results from NIH-DRC-WHO Clinical Trial of Four Experimental Therapies. The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD. The results appear online this week in the New England Journal of Medicine . An announcement made on August 12, 2019 , noted that the study leaders halted the trial early, on August 9, 2019, as recommended by an independent data and safety monitoring board based on its review of preliminary data from 499 study patients. The preliminary analysis found that both mAb114 and REGN-EB3 performed better than ZMapp. The fourth drug, remdesivir, performed...